Switch theme
Sign up to access all valuation multiples
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
2003
161
LTM Revenue $23.4M
Last FY EBITDA -$48.6M
$4.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AC Immune has a last 12-month revenue (LTM) of $23.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, AC Immune achieved revenue of $27.3M and an EBITDA of -$48.6M.
AC Immune expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AC Immune valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $23.4M | XXX | $27.3M | XXX | XXX | XXX |
| Gross Profit | $23.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$48.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -178% | XXX | XXX | XXX |
| EBIT | -$88.6M | XXX | -$52.4M | XXX | XXX | XXX |
| EBIT Margin | -378% | XXX | -192% | XXX | XXX | XXX |
| Net Profit | -$86.2M | XXX | -$50.9M | XXX | XXX | XXX |
| Net Margin | -368% | XXX | -186% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AC Immune's stock price is $2.
AC Immune has current market cap of $173M, and EV of $4.6M.
See AC Immune trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.6M | $173M | XXX | XXX | XXX | XXX | $-0.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AC Immune has market cap of $173M and EV of $4.6M.
AC Immune's trades at 0.2x EV/Revenue multiple, and -0.1x EV/EBITDA.
Equity research analysts estimate AC Immune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AC Immune has a P/E ratio of -2.4x.
See valuation multiples for AC Immune and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $173M | XXX | $173M | XXX | XXX | XXX |
| EV (current) | $4.6M | XXX | $4.6M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/EBIT | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
| EV/Gross Profit | 0.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.4x | XXX | -3.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAC Immune's last 12 month revenue growth is 30%
AC Immune's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
AC Immune's rule of 40 is -321% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AC Immune's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AC Immune and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 30% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -178% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -321% | XXX | -149% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 229% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 292% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AC Immune acquired XXX companies to date.
Last acquisition by AC Immune was XXXXXXXX, XXXXX XXXXX XXXXXX . AC Immune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AC Immune founded? | AC Immune was founded in 2003. |
| Where is AC Immune headquartered? | AC Immune is headquartered in United States of America. |
| How many employees does AC Immune have? | As of today, AC Immune has 161 employees. |
| Who is the CEO of AC Immune? | AC Immune's CEO is Dr. Andrea Pfeifer, PhD. |
| Is AC Immune publicy listed? | Yes, AC Immune is a public company listed on NAS. |
| What is the stock symbol of AC Immune? | AC Immune trades under ACIU ticker. |
| When did AC Immune go public? | AC Immune went public in 2016. |
| Who are competitors of AC Immune? | Similar companies to AC Immune include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of AC Immune? | AC Immune's current market cap is $173M |
| What is the current revenue of AC Immune? | AC Immune's last 12 months revenue is $23.4M. |
| What is the current revenue growth of AC Immune? | AC Immune revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of AC Immune? | Current revenue multiple of AC Immune is 0.2x. |
| Is AC Immune profitable? | Yes, AC Immune is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
